Dr. Phillip J. Koo, MD, discusses the use of radiopharmaceuticals in prostate cancer treatment, as well as the area of theranostics. He goes into detail on the process of choosing these radiopharmaceuticals and trying to determine the best ones to use in various situations in regards to prostate cancer.
Read More
Dr. Phillip J. Koo, MD, discusses the appropriate timing of radium 223 treatments in castration resistant prostate cancer patients, the best approaches to therapeutic layering, and the importance of recognizing bone metastasis when making these therapeutic decisions.
Read More
NEXT GENERATIONnmCRPC ERA 223 Study | Concerns About Using Radium-223 and Abiraterone The...
Read More
Phillip J. Koo, MD, Banner MD Anderson Cancer Center, Phoenix, Arizona discusses how theranostics...
Read More